Containing Natural Gums/resins Patents (Class 424/496)
-
Publication number: 20120064168Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: November 21, 2011Publication date: March 15, 2012Applicant: DEPOMED, INC.Inventors: BRET BERNER, SUI YUEN EDDIE HOU
-
Publication number: 20120058194Abstract: Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.Type: ApplicationFiled: August 25, 2011Publication date: March 8, 2012Inventors: Navin Vaya, Mamta Mishra, Atul Shivaji Shinde, Harshal Prabhakar Bhagwatwar, Debashis Dash, Deepti Jain, Rahul Sudhakar Gawande, Vishal Lad, Sushant Dube, Venkateswarlu Vobalaboina, Srinivas Irukulla, Manikandan Ramalingam
-
Patent number: 8097281Abstract: The present invention relates to dosage forms for oral administration of therapeutic formulations, adapted to provide immediate and/or sustained-release of therapeutic substances, particularly for oral administration of vitamins. There is provided a dosage form for oral administration of a vitamin, comprising: a liquid phase containing a vitamin, e.g. Vitamin C in a relatively fast release form and a solid phase suspended in the liquid phase and containing a vitamin e.g. Vitamin C in a relatively slow release form.Type: GrantFiled: April 6, 2006Date of Patent: January 17, 2012Assignee: GlaxoSmithKline Consumer Healthcare GmbH & Co KGInventors: Stefan Heim, Martina Birgit Schmid, Christoph Walter Theurer
-
Publication number: 20110280945Abstract: The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.Type: ApplicationFiled: November 13, 2009Publication date: November 17, 2011Applicant: Debregeas ET Associes PharmaInventors: Christophe Lebon, Pascal Suplie
-
Publication number: 20110256229Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of said carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: June 30, 2011Publication date: October 20, 2011Applicant: OREXO ABInventors: CHRISTER NYSTROM, SASANNE BREDENBERG
-
Patent number: 8039015Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.Type: GrantFiled: December 7, 2005Date of Patent: October 18, 2011Inventor: Tycho J. Speaker
-
Publication number: 20110244051Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Roger S. FLUGEL
-
Publication number: 20110236493Abstract: A consumer care composition or a food composition comprising a mesoporous microparticulate material wherein at least some of the pores of the material are loaded with at least one ingredient and the loaded mesoporous microparticulate material is encapsulated by a capping layer is described.Type: ApplicationFiled: September 30, 2009Publication date: September 29, 2011Applicant: INTRINSIQ MATERIALS GLOBAL LIMITEDInventors: Leigh Canham, Qurrat Ul Ain Shabir, Armando Loni
-
Publication number: 20110236494Abstract: The present invention relates to oral taste masked pharmaceutical composition comprising ciprofloxacin or salts or esters thereof. It further relates to processes of preparing it.Type: ApplicationFiled: February 25, 2011Publication date: September 29, 2011Applicant: RANBAXY LABORATORIES LIMITEDInventors: Sumit Kumar SAHA, Mona DHALIWAL, Swati AGGRAWAL, Mukesh Kumar GARG, Ajay Kumar SINGLA
-
Patent number: 8021687Abstract: A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tmax of 4-10 hours.Type: GrantFiled: April 7, 2010Date of Patent: September 20, 2011Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane C. Hirsh, Roman V. Rariy, Shubha Chungi, Srinivas G. Rao, Michael T. Heffernan
-
Patent number: 8017152Abstract: Process for producing parenterally administrable cores. The cores are intermediates suitable for manufacturing sustained release preparations. Microcapsules incorporating a core and a shell and pharmaceutical compositions incorporating such cores and microcapsules are also provided.Type: GrantFiled: May 24, 2006Date of Patent: September 13, 2011Assignee: Stratosphere Pharma ABInventors: Nils Ove Gustafsson, Monica Jonsson, Timo Laakso
-
Publication number: 20110200681Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: CIMA LABS INC.Inventors: Walid Habib, Ehab Hamed, Derek Moe, Carrie Kraling, Lisa Hillman
-
Patent number: 7985427Abstract: The invention relates to a gastric juice-resistant device for releasing active substance excipients having delayed intestinal passage from a gastric juice-resistant enclosure, and which serves to increase the active substance concentration in the intestines. The inventive device is characterized in that the active substance excipient containing at least one active substance is provided in the form of a multiparticulate preparation whose individual particles have mucoadhesive properties. The invention also relates to a method for producing said device.Type: GrantFiled: April 22, 2002Date of Patent: July 26, 2011Assignee: LTS Lohmann Therapie-Systeme AGInventors: Despina Solomonidou, Markus Krumme, Bodo Asmussen, Joerg Kreuter
-
Patent number: 7976941Abstract: A low viscosity filler boron nitride agglomerate particles having a generally spherical shape bound together by an organic binder and to a process for producing a BN powder composition of spherically shaped boron nitride agglomerated particles having a treated surface layer which controls its viscosity.Type: GrantFiled: January 6, 2006Date of Patent: July 12, 2011Assignee: Momentive Performance Materials Inc.Inventors: David Lodyga, Joseph W. Tereshko, Ajit Sane, Thomas Fox, Paulo Meneghetti
-
Publication number: 20110123634Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20110123633Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Patent number: 7939105Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: November 19, 1999Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939106Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: May 23, 2003Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20110091563Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.Type: ApplicationFiled: March 10, 2009Publication date: April 21, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takashi Kurasawa, Yasuko Watanabe, Yoshihiro Omachi
-
Patent number: 7923035Abstract: The humidity-dependent antibacterial powdery composition comprises a volatile oily antibacterial substance contained in a high ratio and a water-soluble film forming agent and the behavior of release of the antibacterial substance is changed depending on humidity. The process for producing the same is characterized in that a water-soluble film forming agent optionally together with a powder vehicle is dissolved and/or dispersed in water, subsequently a volatile oily antibacterial substance optionally together with an emulsifying agent is added to the solution and emulsified, and thereafter the obtained emulsion is spray dried into powder. The humidity-dependent antibacterial food storing article is characterized by carrying the humidity-dependent antibacterial powdery composition. The method of storing food is characterized in that the volatile oily antibacterial substance is released from the humidity-dependent antibacterial food storing article toward food lying in an atmosphere of 70% or higher humidity.Type: GrantFiled: October 22, 2003Date of Patent: April 12, 2011Assignee: Mitsubishi-Kagaku Foods CorporationInventors: Shigeo Ii, Asami Takata, Yuichi Mizukami, Ikuo Yashiki
-
Patent number: 7897177Abstract: A particulate fiber composition containing at least one first dietary fiber, coated by an insoluble dietary fiber or a dietary fiber with low solubility, serving to prevent dissolution of the fiber composition in the oral cavity and during passage through the esophagus. The fiber composition has one or several inserted additional layers of at least one second dietary fiber between the at least one first dietary fiber and the coating of the insoluble dietary fiber/dietary fiber of low solubility. The different properties of solubility and fermentability of the fibers are utilized for the production of multilayer particles. The dietary fiber composition can be used as a supplement applied in pharmaceuticals and food products where high fiber content and small calorie content is given a high priority. Furthermore, the dietary fiber supplement can be applied for replacement of part of the sugar in sugar coatings of generally known cereals.Type: GrantFiled: October 19, 2004Date of Patent: March 1, 2011Assignee: Medic House Cambrige LtdInventors: Lasse L. Hessel, Jesper Malling, Eivind Gudmand-Høyer
-
Publication number: 20100297246Abstract: Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-?B signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions.Type: ApplicationFiled: September 5, 2008Publication date: November 25, 2010Inventors: Mervyn Neale Weitzmann, George Richard Beck, Jin-Kyu Lee
-
Patent number: 7838037Abstract: The present invention provides methods for microencapsulation of active ingredients for topical application, whereby double-layer and triple-layer microcapsules are obtained. The microcapsules protect the active ingredients, maintain their original activity throughout processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the skin.Type: GrantFiled: August 22, 2005Date of Patent: November 23, 2010Assignee: Tagra Biotechnologies Ltd.Inventors: Emma Kvitnitsky, Yury Shapiro, Olga Privalov, Irena Oleinik, Igor Polisher
-
Publication number: 20100291224Abstract: The present invention provides a core-shell nanostructure comprising: a hydrophobic polymeric core; and a hydrophobic polymeric shell on the core, wherein the shell comprises at least one binding site for binding at least one target agent. In particular, the nanostructure has a red-blood cell morphology. The present invention also provides a method for preparing the nanostructure and uses of the nanostructure.Type: ApplicationFiled: January 5, 2009Publication date: November 18, 2010Inventors: Yen Wah Tong, Chau Jin Tan, Hong Gap Chua, Kwee Hong Ker, Niranjani Sankarakumar
-
Patent number: 7807194Abstract: The present invention is directed to a homogeneous, thermoreversible gel film comprising a film forming amount of kappa-2 carrageenan, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and processes for the preparation thereof. The present invention is also directed to soft capsules and solid forms containing the gel film, as well as processes for the preparation thereof.Type: GrantFiled: April 14, 2004Date of Patent: October 5, 2010Assignee: FMC CorporationInventors: James J. Modliszewski, Arthur D. Ballard, Christopher J. Sewall, William R. Blakemore, Peter J. Riley
-
Publication number: 20100233276Abstract: The described agglomeration of drug microparticles blended with excipient microparticles is a technique for the size enlargement of micronized products that could be damaged by granulation or compaction techniques. These agglomerates can be used as oral prompt or delayed-release dosage forms administered as they are or dispersed in a liquid. The composition and quantity of the excipient microparticles resulted to be the crucial factors for the agglomerate quality. Therefore, adjusting the content of surface-active agent between 8-20%, of the excipient microparticles it is possible to agglomerate microparticles of drugs that could not be agglomerated per se. Increasing the surfactant concentration in the spray-dried excipient microparticles or increasing the fraction of these excipient microparticles in the blend, the agglomeration was improved. The spray drying technique concentrates the surface-active agent on the microparticle surface.Type: ApplicationFiled: October 26, 2007Publication date: September 16, 2010Applicant: UNIVERSITA' DEGLI STUDI DI PARMAInventors: Renata Raffin, Paolo Colombo, Fabio Sonvico, Gaia Colombo, Alessandra Rossi, Francesca Buttini
-
Publication number: 20100196472Abstract: A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tmax of 4-10 hours.Type: ApplicationFiled: April 7, 2010Publication date: August 5, 2010Applicant: Collegium Pharmaceutical, Inc.Inventors: Jane C. HIRSH, Roman V. Rariy, Shubha Chungi, Srinivas G. Rao, Michael T. Heffernan
-
Publication number: 20100178337Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.Type: ApplicationFiled: December 18, 2009Publication date: July 15, 2010Applicant: Flamel TechnologiesInventors: Rémi MEYRUEIX, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
-
Publication number: 20100173002Abstract: Disclosed are microcapsules and methods for preparing and using them, as well as methods for improving various properties of microcapsules like impermeability.Type: ApplicationFiled: June 4, 2007Publication date: July 8, 2010Inventors: Jin Yulai, Colin James Barrow, Wei Zhang, Cuie Yan, Jonathan Michael Curtis, Shawn Moulton, Nancy Beatrice Diogbenou, Lesek Alexa Webber
-
Patent number: 7727629Abstract: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.Type: GrantFiled: July 15, 2004Date of Patent: June 1, 2010Assignee: Ocean Nutrition Canada LimitedInventor: Nianxi Yan
-
Patent number: 7700131Abstract: Powders having contact biocidal properties comprise a polysaccharide carrying atomic/metallic silver. The preferred polysaccharide is chitin, although other polysaccharides including chitosan, carboxymethyl celluloses and carrageenans can be used. The chitin may be obtained from deproteinated crustacean shells without demineralisation, thus being admixed with calcium carbonate and other naturally occurring minerals present in the shells, and may be enzyme deacetylated. The powders of the invention can be used as biocidal dusting powders, formulated into pastes, gels, hydrogels, creams, foams and aerosol sprays for pharmaceutical applications, or dissolved to form solutions for coating substrates such as skin, fabrics, glass, leather and paper to give a bactericidal surface. A particular application of such a solution is as a protective, post-wash treatment for workwear in a laundering process.Type: GrantFiled: July 18, 2005Date of Patent: April 20, 2010Assignee: Chitoproducts LimitedInventors: Alan Taylor, George Andrew Francis Roberts, Frances Ann Wood
-
Publication number: 20100080851Abstract: The present invention provides a preparing method of microcapsule containing unsaturated fatty acid comprising the steps of (a) preparing a first coating material by mixing and gelatinating one or more gums selected from the group consisting of xanthan gum, guar gum, and locusbean gum, with poly glycerin esters of fatty acid in sterilized water, adding unsaturated fatty acid to the solution, and homogenizing the solution; (b) preparing a second coating material by mixing and gelatinating starch or modified starch, gelatin or casein, and poly glycerin esters of fatty acid in sterilized water, adding the first coating material prepared in (a) to the solution, and homogenizing the solution; and (c) spraying the second coating material prepared in (b) in cold sterilized water; a microcapsule prepared by the method; and articles containing the microcapsule. The present microcapsule has effects of preventing the oxidation of unsaturated fatty acid and inhibiting offensive smell.Type: ApplicationFiled: July 27, 2007Publication date: April 1, 2010Applicant: CHEBIGEN INC.Inventors: Hong-Sig Sin, Si-Ho Park, Soo-Jong Um, Jong-Hyun Lee, Hee-Jeong Kim, Ha-Lyong Jin, Hyoung-Su Kim
-
Patent number: 7687071Abstract: Nanoparticulate preparations of pharmaceutical and cosmetic active substances with a core-shell structure, whereby the active substance is present in an X-ray amorphous form, together with a polymer matrix and the shell consists of a stabilizing sheathing matrix.Type: GrantFiled: December 7, 1999Date of Patent: March 30, 2010Assignee: BASF AktiengesellschaftInventors: Robert Heger, Helmut Auweter, Jörg Breitenbach, Heribert Bohn
-
Publication number: 20100074955Abstract: The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.Type: ApplicationFiled: September 18, 2007Publication date: March 25, 2010Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Helmut Heinrich Buschmann, Xavier Codony-Soler
-
Patent number: 7670627Abstract: The present invention relates to a novel pH triggered, targeted controlled release system. The controlled delivery system of the present invention is substantially a free-flowing powder formed of solid hydrophobic nano-spheres comprising pharmaceutical active ingredients that are encapsulated in a pH sensitive micro-spheres. The invention also relates to the processes for preparing the compositions and processes for using same. The controlled release system can be used to target and control the release of pharmaceutical active ingredients onto certain regions of the gastrointestinal tract including the stomach and the small intestine. The invention further pertains to pharmaceutical products comprising the controlled release system of the present invention.Type: GrantFiled: December 9, 2002Date of Patent: March 2, 2010Assignee: Salvona IP LLCInventors: Adi Shefer, Samuel David Shefer
-
Publication number: 20100028452Abstract: A delivery system for inclusion in an edible composition is formulated to have at least one active component encapsulated within an encapsulating material, whereby the delivery system has a tensile strength suitable for delivering the active component at a desired release rate.Type: ApplicationFiled: October 13, 2009Publication date: February 4, 2010Applicant: Cadbury Adams USA LLCInventors: Navroz BOGHANI, Petros Gebreselassie
-
Publication number: 20090311336Abstract: A particle having an average diameter from 80 to 500 nm and having a core containing at least one compound having a ?max in the range from 250 to 400 nm and a cross-linked polymeric shell.Type: ApplicationFiled: June 9, 2009Publication date: December 17, 2009Inventors: Charles Elwood Jones, Morris Christopher Wills
-
Publication number: 20090304792Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.Type: ApplicationFiled: July 31, 2007Publication date: December 10, 2009Applicant: ETHYPHARMInventor: Didier Hoarau
-
Publication number: 20090269399Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: ApplicationFiled: April 10, 2009Publication date: October 29, 2009Applicant: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20090246275Abstract: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.Type: ApplicationFiled: March 10, 2009Publication date: October 1, 2009Inventors: John O'Gara, Sonali Puri
-
Patent number: 7510729Abstract: The invention relates to the combination of polyvinyl acetate and water-insoluble, acid-insoluble, or alkali-insoluble polymers used for producing film coatings for forms of administration in which agents are released in a controlled manner, and methods for the production thereof. The controlled-release properties can be specifically adjusted by means of said combinations, resulting in films having excellent mechanical stability and storage stability. In particular, agents are released independent of the pH by means of the inventive forms of administration.Type: GrantFiled: March 11, 2003Date of Patent: March 31, 2009Assignee: BASF AktiengesellschaftInventors: Karl Kolter, Roland Bodmeier, Andriy Dashevskiy
-
Patent number: 7442385Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: May 16, 2006Date of Patent: October 28, 2008Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Patent number: 7438930Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.Type: GrantFiled: July 17, 2007Date of Patent: October 21, 2008Assignee: Purdue PharmaInventors: Thinnayam N. Krishnamurthy, Andrew Darke
-
Patent number: 7413781Abstract: This invention provides novel methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as carriers for biologically active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species, which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization.Type: GrantFiled: December 22, 2006Date of Patent: August 19, 2008Assignee: Board of Regents, The University of Texas SystemInventors: Jeffrey A. Hubbell, Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Neil P. Desai, Syed F. A. Hossainy
-
Publication number: 20080175919Abstract: The present invention includes a urea powder, the particles of which are encapsulated in a dimethicone and silica network, prior to being incorporated into anhydrous compositions. The encapsulated urea is capable of imparting a cooling activity to a topical composition. The invention also pertains to topical, cooling compositions containing an encapsulated urea. The encapsulated urea is new and its use to impart a cooling activity to topical anhydrous compositions is new. Topical, anhydrous compositions comprising the encapsulated urea are also new. Anhydrous compositions containing the urea are stable against hydrolysis that might otherwise occur due to the ambient humidity. Disclosed compositions create a clean and fresh feel for a user.Type: ApplicationFiled: January 22, 2007Publication date: July 24, 2008Inventors: Fatemeh Mohammadi, Kathleen James-Lawrence, Barbara Crockett
-
Publication number: 20080152719Abstract: The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) optionally a neutral core (nonpareilles), b) an inner controlling layer comprising a substance having a modulating effect, which is embedded in a matrix which influences the delivery of the modulatory substance and which comprises pharmaceutically usable polymers, waxes, resins and/or proteins, and where appropriate an active ingredient, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth) acrylate copolymers where the outer controlling layer has a thickness from 20 to less than 55 ?m and contains 0,1 to 10% by weight of glycerol monostearate, where the multiparticulate pharmaceutical form contains 20 to 60% by weight of the pellets, which are compresType: ApplicationFiled: March 3, 2006Publication date: June 26, 2008Applicant: ROEHM GMBHInventors: Hans-Ulrich Petereit, Rosario Lizio, Hema Ravishankar, Ashwini Samel
-
Patent number: 7303766Abstract: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care compositions, thereby rendering the overall composition ineffective for its intended purpose, particularly if the calcium silicate is present in its usual state at high loading levels. Alternatively, if certain materials present within personal care compositions exhibit a sufficiently low pH level, the effectiveness of such calcium silicates may be compromised as well.Type: GrantFiled: February 3, 2005Date of Patent: December 4, 2007Assignee: J.M. Huber CorporationInventors: Michael C. Withiam, Donald P. Conley, Michael Simone
-
Patent number: 7303767Abstract: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care compositions, thereby rendering the overall composition ineffective for its intended purpose, particularly if the calcium silicate is present in its usual state at high loading levels. Alternatively, if certain materials present within personal care compositions exhibit a sufficiently low pH level, the effectiveness of such calcium silicates may be compromised as well.Type: GrantFiled: February 3, 2005Date of Patent: December 4, 2007Assignee: J.M. Huber CorporationInventors: Michael C. Withiam, Donald P. Conley, Michael Simone
-
Patent number: 7235261Abstract: This invention relates to a controlled release encapsulated dry powder that is formed by an emulsion comprising: A) a fully hydrolyzed polymer, B) a hydrophobic silica, C) a modified corn starch, and D) at least one fragrance oil, which is emulsified in water and spray dried to evaporate the water obtaining the encapsulated dry powder. This invention also relates to a process for the preparation of a controlled release encapsulated dry powder that is formed by an emulsion, which is spray dried. The controlled release encapsulated dry powder is used in deodorant and antiperspirant applications.Type: GrantFiled: June 27, 2002Date of Patent: June 26, 2007Assignee: Haarmann & Reimer CorporationInventors: Leslie C. Smith, Steven G. Mushock, Keith J. McDermott
-
Patent number: RE40059Abstract: A process for stabilizing a sensitive substance; (a) plating a sensitive substance onto a solid carrier under a controlled atmosphere to reduce loss of the sensitive substance; (b) encapsulating the plated material under controlled atmosphere and airflow to reduce volatilization during the process and stabilize the sensitive substance.Type: GrantFiled: November 29, 2001Date of Patent: February 12, 2008Assignee: Balchem CorporationInventors: Carl J. Pacifico, Wen-Hsin Wu, Marta Fraley